Hikma Pharmaceuticals files US antitrust claims against Amarin over Vascepa
MLex Summary: Amarin Pharma has been accused of illegally delaying generic competition for the branded cardiovascular drug Vascepa. Hikma Pharmaceuticals claims Amarin used exclusivity agreements to prevent any suppliers of a...To view the full article, register now.
Already a subscriber? Click here to view full article